Poor
Mostly Inaccurate
Patient Risk:
Moderate
Summary
Some general mechanism/indication statements align with the label excerpts, but multiple herb–drug bleeding/platelet-aggregation claims are not supported by the provided FDA label text and therefore are likely unsafe/unsupported relative to the supplied prescribing information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
Supported indirectly by label mechanism (12.1) and lipid-lowering indications (1.2, 14.2); label excerpts do not explicitly state 'statin' or 'lower cholesterol in the blood' phrasing, but the indication and mechanism support cholesterol-lowering.
Lipitor works by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver.
Mechanism of action: 'Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.' (12.1).
Reducing cholesterol production with Lipitor decreases the risk of heart disease and stroke.
Label provides cardiovascular prevention indications to reduce MI and stroke risk (1.1 and 1.2) and additional cardiovascular outcomes in clinical studies (14.1).
Unsupported Statements
Ginkgo biloba can increase the risk of bleeding when taken with Lipitor due to its blood-thinning properties.
No herb-specific interaction or bleeding/platelet effect for ginkgo is present in the provided label excerpts (Sections 7.x cover drug interactions but no ginkgo).
Garlic can increase the risk of bleeding when taken with Lipitor due to its blood-thinning properties and inhibition of platelet aggregation.
No garlic–atorvastatin interaction or bleeding/platelet-aggregation mechanism is supported in the provided label excerpts.
Feverfew can increase the risk of bleeding when taken with Lipitor due to its inhibition of platelet aggregation.
No feverfew–atorvastatin interaction or bleeding/platelet-aggregation mechanism is supported in the provided label excerpts.
Ginseng can increase the risk of bleeding when taken with Lipitor due to its inhibition of platelet aggregation.
No ginseng–atorvastatin interaction or bleeding/platelet-aggregation mechanism is supported in the provided label excerpts.
St. John's Wort can reduce the effectiveness of Lipitor by inducing the metabolism of Lipitor.
The provided label excerpts for drug interactions (7, 7.1–7.3) do not mention St. John's Wort; no on-label support for this specific claim is present.
Turmeric (curcumin) can increase the risk of bleeding when used with Lipitor.
No turmeric–atorvastatin interaction or bleeding risk statement is supported in the provided label excerpts.
Cayenne pepper (capsaicin) can increase the risk of bleeding when used with Lipitor.
No cayenne/capsaicin–atorvastatin interaction or bleeding risk statement is supported in the provided label excerpts.
Echinacea can increase the risk of bleeding when used with Lipitor.
No echinacea–atorvastatin interaction or bleeding risk statement is supported in the provided label excerpts.
Contradictions
Important Omissions
For the stated cardiovascular risk reduction claim ('heart disease and stroke'), the label excerpts specify the outcomes as myocardial infarction and stroke and also include other outcomes (e.g., revascularization/angina depending on population); a precise mapping to the label wording is omitted.
Importance:
Low
The herb–drug interaction claims omit any label-based basis such as specified concomitant drug classes/doses (e.g., strong CYP 3A4 inhibitors, etc.).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple interaction claims (herbs increasing bleeding risk or reducing effectiveness) are not supported by the provided FDA label excerpts; asserting these without label support could mislead about safety or efficacy risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Inaccurate
Primary Issue
Herb–atorvastatin interaction and bleeding/platelet-aggregation claims are unsupported by the provided label excerpts.
Suggested Improvement
Remove or replace herb-specific interaction claims with label-supported interaction information (e.g., strong CYP3A4 inhibitors, grapefruit juice, cyclosporine dosing limitations, and caution with certain drug classes) and use the label’s exact cardiovascular outcome wording where applicable.